Loading…
Loading…
Announcements from Anixa Biosciences, published the moment they cross the wire. Get them by email.
2020
Apr 23, 2020
7:00 AM EDT
The publication of a peer-reviewed journal article in Biomarker Insights. The article, entitled "Detecting Prostate Cancer Using Pattern Recognition Neural Networks with Flow Cytometry-Based Immunophenotyping in At-Risk Men," supports the use of Anixa's Cchek™ early cancer detection technology as a tool to improve…
Apr 20, 2020
6:30 AM EDT
It has entered into a strategic collaboration with OntoChem GmbH to discover and develop anti-viral drug candidates for COVID-19.
Mar 02, 2020
7:00 AM EST
Data related to Anixa's recently launched Cchek™ Prostate Cancer Confirmation test (Cchek™ PCC) will be presented at the "AI and Big Data in Cancer: From Innovation to Impact" conference. Cchek™ is Anixa's artificial intelligence (AI) driven cancer detection technology.
Feb 12, 2020
7:00 AM EST
The research team lead by Dr. Jose Conejo-Garcia , Chair of the Department of Immunology at Moffitt Cancer Center, Anixa's development partner, has completed and validated the reformulation of the viral vector necessary for its CAR-T program.
Jan 06, 2020
7:00 AM EST
Data from studies utilizing Cchek™, the company's artificial intelligence (AI) driven cancer detection technology, will be presented at the American Association for Cancer Research (AACR) Special Conference on Advances in Liquid Biopsies.
2019
Dec 23, 2019
7:00 AM EST
Its chief executive officer, Dr. Amit Kumar , will present at the Biotech Showcase 2020 conference being held January 13-15, 2020 at the Hilton San Francisco Union Square in San Francisco, California .
Dec 16, 2019
6:45 AM EST
The commercial launch of its Cchek™ Prostate Cancer Confirmation test (Cchek™ PCC), the first test developed with the Cchek™ artificial intelligence driven, flow cytometry based, liquid biopsy technology platform.
Dec 13, 2019
5:45 PM EST
It will hold a conference call on December 17, 2019 at 1:30 p.m. Pacific / 4:30 p.m. Eastern to discuss the progress made and the future plans for its Cchek TM artificial intelligence based cancer diagnostic test and its CAR-T based ovarian cancer therapeutic and breast cancer vaccine programs.
Dec 13, 2019
6:45 AM EST
An update regarding the chimeric antigen receptor T-cell (CAR-T) technology it is developing with its partner, Moffitt Cancer Center.
Dec 02, 2019
7:00 AM EST
Data from its ongoing studies utilizing Cchek™, its artificial intelligence (AI) driven early cancer detection technology will be presented during a poster session at the San Antonio Breast Cancer Symposium (SABCS).
Nov 26, 2019
7:00 AM EST
The addition of Genesis Research, LLC to the ongoing Cchek™ prostate cancer detection study.
Nov 22, 2019
7:00 AM EST
A collaboration with Urology Centers of Alabama (UCA) in the Cchek™ early prostate cancer detection study. UCA will provide patient samples in Anixa's ongoing study, including support of clinical validation of Anixa's Cchek™ Prostate Cancer Confirmation test.
Nov 20, 2019
7:00 AM EST
Its collaboration with Idaho Urologic Institute, PA (IUI) in the Cchek™ early cancer detection study. IUI will provide patient samples for Anixa's ongoing prostate cancer study, including support of clinical validation of Anixa's Cchek™ Prostate Cancer Confirmation test.
Nov 07, 2019
7:00 AM EST
Data from its ongoing studies utilizing Cchek™, its artificial intelligence (AI) driven early cancer detection technology will be displayed in a poster presentation at the Cell Symposia: Hallmarks of Cancer.
Nov 05, 2019
7:00 AM EST
The United States Patent and Trademark Office (USPTO) has issued US Patent No. 10,463,724 titled "Breast Cancer Vaccine."
Oct 28, 2019
7:00 AM EDT
The appointment of Emanuele Ostuni , Ph.D. to its Scientific Advisory Board.
Oct 25, 2019
7:00 AM EDT
Its collaboration with Urology San Antonio, PA in Anixa's ongoing Cchek™ prostate cancer study.
Oct 22, 2019
7:00 AM EDT
The acceptance of an abstract at the 34 th Annual Meeting of the Society for Immunotherapy of Cancer (SITC). A poster presentation will include data from ongoing studies utilizing Cchek™, the company's artificial intelligence (AI) driven cancer detection technology.
Oct 15, 2019
7:00 AM EDT
The appointment of Thomas Schlumpberger , Ph.D., as Executive Vice President, Diagnostics. Dr. Schlumpberger will be responsible for the development and commercialization of Cchek™, Anixa's artificial intelligence driven liquid biopsy for early cancer detection.
Oct 10, 2019
7:00 AM EDT
The appointment of Ian H. Frazer , MD, AC, FRS, FAA, to its Scientific Advisory Board.
